Uroplasty (UPI) 3.26 $UPI
Uroplasty To Announce Fourth Quarter And Fiscal Year 2014 Financial Results On May 15, 2014
PR Newswire - Thu May 01, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the fourth quarter and fiscal year 2014 ended March 31, 2014 at the market close on Thursday, May 15, 2014.
Uroplasty Names Daniel P. Merz As Vice President Of Healthcare Affairs
PR Newswire - Thu Apr 17, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Daniel P. Merz has joined the Company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the Company's products. He joins Uroplasty with fifteen years of medical device experience, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances.
Becton, Dickinson Gets CLIA-Waiver for RSV Test System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:00PM CDT
BD Veritor System is the third FDA-cleared and CLIA-waived offering of Becton, Dickinson.
Uroplasty To Participate In The ROTH 26th Annual Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross
PR Newswire - Thu Feb 06, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. IBC covers 2.2 million lives and this decision provides patient coverage for ongoing treatments for up to two years. IBC is the leading health insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
Can the Rally in Uroplasty (UPI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:48AM CST
Can the Rally in Uroplasty (UPI) Shares Continue?
Becton, Dickinson Tops Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 1:48PM CST
International revenues grew 8.9% to $1.17 billion in the quarter, driven by continued strength in emerging markets.
Align Up on Better than Expected Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 11:48AM CST
Align Technology reported its fourth quarter and full year 2013 financial results.
Cardinal Health Tops Earnings Ests, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:30PM CST
Cardinal Health's net adjusted earnings slid 1.3% to $313 million from $317 million reported in the second quarter of fiscal 2013.
Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
PR Newswire - Mon Jan 27, 3:05PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company's product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.
Strength Seen in Uroplasty, Inc. (UPI) as Stock Shoots Up 28.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 7:44AM CST
Uroplasty, Inc. was a big mover last session, as the company saw its shares escalate over 28% on the day.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Uroplasty (UPI) Hit A Two-Year High Today
at The Street - Fri Jan 24, 2:50PM CST
Uroplasty (UPI) hits a two-year high of $5.40 on Friday after the company reported revenue of $6.4 million, up 14% from the same period one year earlier. Domestic sales of the company's Urgent PC Neuromodulation System grew 19% to $3.2 million, up...
Uroplasty Reports Record Quarterly Revenue
PR Newswire - Thu Jan 23, 3:01PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Rubenstein Public Relations Appoints New Director Of Communications And Associate Vice President
PR Newswire - Tue Jan 14, 7:32PM CST
Richard Rubenstein, President of Rubenstein Public Relations (RPR), announced today that the agency welcomed two new hires: Roxanne Ducas as Director of Communications and Katalin Bergou as an Associate Vice President. With a breadth of experience in media and public relations, both women bring extensive backgrounds in corporate communications to RPR's team. RPR continues to rise in stature as one of the nation's leading public relations agencies.
Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
PR Newswire - Thu Jan 09, 1:49PM CST
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2014 ended December 31, 2013 at the market close on Thursday, January 23, 2014.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual
PR Newswire - Mon Dec 23, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.
Uroplasty Names David B. Perry Vice President Of Marketing
PR Newswire - Tue Dec 10, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.
Uroplasty Provides Update On PTNS Reimbursement
PR Newswire - Wed Dec 04, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Uroplasty To Announce Fourth Quarter And Fiscal Year 2014 Financial Results On May 15, 2014
PR Newswire - Thu May 01, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the fourth quarter and fiscal year 2014 ended March 31, 2014 at the market close on Thursday, May 15, 2014.
Uroplasty Names Daniel P. Merz As Vice President Of Healthcare Affairs
PR Newswire - Thu Apr 17, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Daniel P. Merz has joined the Company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the Company's products. He joins Uroplasty with fifteen years of medical device experience, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances.
Becton, Dickinson Gets CLIA-Waiver for RSV Test System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:00PM CDT
BD Veritor System is the third FDA-cleared and CLIA-waived offering of Becton, Dickinson.
Uroplasty To Participate In The ROTH 26th Annual Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross
PR Newswire - Thu Feb 06, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. IBC covers 2.2 million lives and this decision provides patient coverage for ongoing treatments for up to two years. IBC is the leading health insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
Can the Rally in Uroplasty (UPI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:48AM CST
Can the Rally in Uroplasty (UPI) Shares Continue?
Becton, Dickinson Tops Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 1:48PM CST
International revenues grew 8.9% to $1.17 billion in the quarter, driven by continued strength in emerging markets.
Align Up on Better than Expected Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 11:48AM CST
Align Technology reported its fourth quarter and full year 2013 financial results.
Cardinal Health Tops Earnings Ests, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:30PM CST
Cardinal Health's net adjusted earnings slid 1.3% to $313 million from $317 million reported in the second quarter of fiscal 2013.
Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
PR Newswire - Mon Jan 27, 3:05PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company's product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.
Strength Seen in Uroplasty, Inc. (UPI) as Stock Shoots Up 28.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 7:44AM CST
Uroplasty, Inc. was a big mover last session, as the company saw its shares escalate over 28% on the day.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Uroplasty (UPI) Hit A Two-Year High Today
at The Street - Fri Jan 24, 2:50PM CST
Uroplasty (UPI) hits a two-year high of $5.40 on Friday after the company reported revenue of $6.4 million, up 14% from the same period one year earlier. Domestic sales of the company's Urgent PC Neuromodulation System grew 19% to $3.2 million, up...
Uroplasty Reports Record Quarterly Revenue
PR Newswire - Thu Jan 23, 3:01PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Rubenstein Public Relations Appoints New Director Of Communications And Associate Vice President
PR Newswire - Tue Jan 14, 7:32PM CST
Richard Rubenstein, President of Rubenstein Public Relations (RPR), announced today that the agency welcomed two new hires: Roxanne Ducas as Director of Communications and Katalin Bergou as an Associate Vice President. With a breadth of experience in media and public relations, both women bring extensive backgrounds in corporate communications to RPR's team. RPR continues to rise in stature as one of the nation's leading public relations agencies.
Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
PR Newswire - Thu Jan 09, 1:49PM CST
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2014 ended December 31, 2013 at the market close on Thursday, January 23, 2014.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual
PR Newswire - Mon Dec 23, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.
Uroplasty Names David B. Perry Vice President Of Marketing
PR Newswire - Tue Dec 10, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.
Uroplasty Provides Update On PTNS Reimbursement
PR Newswire - Wed Dec 04, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
